loading
Precedente Chiudi:
$45.12
Aprire:
$45.18
Volume 24 ore:
8.51M
Relative Volume:
3.03
Capitalizzazione di mercato:
$7.61B
Reddito:
$217.77M
Utile/perdita netta:
$-438.86M
Rapporto P/E:
-18.61
EPS:
-2.41
Flusso di cassa netto:
$-456.33M
1 W Prestazione:
+7.50%
1M Prestazione:
+35.53%
6M Prestazione:
+60.27%
1 anno Prestazione:
+78.02%
Intervallo 1D:
Value
$44.20
$45.48
Intervallo di 1 settimana:
Value
$41.30
$45.48
Portata 52W:
Value
$21.72
$45.48

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
Nome
Bridgebio Pharma Inc
Name
Telefono
(650) 391-9740
Name
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Name
Dipendente
730
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
BBIO's Discussions on Twitter

Confronta BBIO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BBIO
Bridgebio Pharma Inc
44.86 7.61B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-31 Iniziato Redburn Atlantic Buy
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-10-03 Iniziato Oppenheimer Perform
2024-09-04 Iniziato Piper Sandler Overweight
2024-03-21 Ripresa Raymond James Outperform
2024-01-31 Iniziato BMO Capital Markets Market Perform
2023-12-08 Iniziato Wells Fargo Overweight
2023-11-07 Iniziato Citigroup Buy
2023-10-24 Iniziato Cantor Fitzgerald Overweight
2023-07-18 Downgrade Jefferies Buy → Hold
2023-04-19 Iniziato Evercore ISI Outperform
2023-02-06 Iniziato Cowen Outperform
2021-12-27 Reiterato Mizuho Buy
2021-12-27 Reiterato SVB Leerink Outperform
2021-09-10 Aggiornamento BofA Securities Neutral → Buy
2021-05-21 Iniziato UBS Buy
2021-03-22 Reiterato Goldman Buy
2021-02-22 Ripresa JP Morgan Overweight
2021-02-09 Ripresa Goldman Buy
2021-01-11 Reiterato H.C. Wainwright Buy
2020-12-10 Reiterato H.C. Wainwright Buy
2020-06-25 Iniziato BofA/Merrill Neutral
2020-05-19 Iniziato BTIG Research Buy
2020-04-13 Iniziato H.C. Wainwright Buy
2020-02-19 Iniziato Mizuho Buy
2019-07-26 Iniziato Raymond James Outperform
2019-07-22 Iniziato BMO Capital Markets Outperform
2019-07-22 Iniziato Goldman Buy
2019-07-22 Iniziato JP Morgan Overweight
2019-07-22 Iniziato Jefferies Buy
2019-07-22 Iniziato Piper Jaffray Overweight
2019-07-22 Iniziato SVB Leerink Outperform
Mostra tutto

Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie

pulisher
Jun 18, 2025

10 Biotech Stocks Screaming a Buy - Insider Monkey

Jun 18, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on BBIO with Outperform Rating - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on BBIO with Outperform Rating | BBIO Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

BridgeBio (BBIO) Gains Positive Outlook with Strong Transthyreti - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 16, 2025

BridgeBio (BBIO) Receives Outperform Rating from Wolfe Research | BBIO Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

BridgeBio Pharma stock reaches 52-week high at $40.45 By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

BridgeBio Pharma stock reaches 52-week high at $40.45 - Investing.com

Jun 16, 2025
pulisher
Jun 14, 2025

BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright - MSN

Jun 14, 2025
pulisher
Jun 14, 2025

BridgeBio Pharma’s SWOT analysis: stock poised for growth amid challenges - Investing.com

Jun 14, 2025
pulisher
Jun 12, 2025

When the Price of (BBIO) Talks, People Listen - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Comments on BBIO FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 10, 2025

BridgeBio Pharma (NASDAQ:BBIO) Given New $56.00 Price Target at HC Wainwright - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Day 8 of Gains Streak for BridgeBio Pharma Stock with 21% Return (vs. 42% YTD) [6/9/2025] - Trefis

Jun 10, 2025
pulisher
Jun 09, 2025

BridgeBio stock holds Buy rating, price target at $56H.C. Wainwright - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwri - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio (BBIO) Price Target Raised to $56 by H.C. Wainwright | - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : BridgeBio Pharma, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwright & Co. | BBIO Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio (BBIO) Price Target Raised to $56 by H.C. Wainwright | BBIO Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Breakthrough Growth in Transthyretin Amyloid Cardiomyopathy - openPR.com

Jun 09, 2025
pulisher
Jun 07, 2025

Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

BridgeBio Pharma stock hits 52-week high at $39.58 By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

BridgeBio Pharma stock hits 52-week high at $39.58 - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Piper Sandler maintains overweight rating on BridgeBio Pharma stock - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Piper Sandler maintains overweight rating on BridgeBio Pharma stock By Investing.com - Investing.com UK

Jun 06, 2025
pulisher
Jun 05, 2025

BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

BridgeBio price target raised to $42 from $37 at BMO Capital - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

BMO Capital raises BridgeBio Pharma stock price target to $42 By Investing.com - Investing.com UK

Jun 04, 2025
pulisher
Jun 04, 2025

BridgeBio (BBIO) Target Price Raised by BMO Capital | BBIO Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Exploring High Growth Tech Stocks In The US Market - simplywall.st

Jun 04, 2025
pulisher
Jun 04, 2025

BridgeBio: New Data Bolsters The Bull Case (NASDAQ:BBIO) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 02, 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

BridgeBio Management Reveals Latest Genetic Disease Strategy at Goldman Sachs Healthcare Conference 2025 - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

BridgeBio Pharma (NASDAQ:BBIO) Rating Lowered to “Sell” at Wall Street Zen - Defense World

Jun 01, 2025
pulisher
May 28, 2025

Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 28, 2025
pulisher
May 27, 2025

Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st

May 27, 2025
pulisher
May 26, 2025

BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria

May 26, 2025
pulisher
May 26, 2025

Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com

May 26, 2025
pulisher
May 24, 2025

Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 24, 2025
pulisher
May 21, 2025

The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha

May 21, 2025
pulisher
May 21, 2025

BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey

May 21, 2025
pulisher
May 21, 2025

Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com

May 21, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan

May 20, 2025
pulisher
May 19, 2025

BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria

May 19, 2025

Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Capitalizzazione:     |  Volume (24 ore):